Therapeutic antibodies represent a rapidly advancing class of drugs, characterized by strong affinity, high specificity, long half-life and potent pharmacological efficacy. These features not only confine the application of therapeutic antibodies to the standard full-length IgG form but also extend to new formats, including antibody fragments (scFv, VHH), cell therapies (CAR-T), drug conjugates (ADC) and bispecific antibodies. As numerous antibody therapies continue to progress through preclinical development and clinical trials, the demand for biological analysis, such as immunogenicity analysis and pharmacokinetics, is gradually increasing for these projects. In this context, anti-idiotype antibodies (anti-IDs) have become one of the preferred choices for preclinical and clinical stage biological analysis applications.

Depending on the type of antibody drug under examination, anti-IDs targeting antigen blocking, non-blocking and drug-target complexes are developed to accommodate different detection methods for free, bound and total antibody drugs.

Rabbit-derived antibodies are well-known for their high affinity and diversity, along with smaller recognition epitopes to enhance antibody sensitivity. Leveraging our proprietary rabbit single B cell antibody development platform, We provide a one-stop service for the development of anti-idiotype antibodies, covering the entire process.